These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hospitalization risk in patients with schizophrenia before and after initiation of risperidone long-acting injection in Japan. Yoshimura B; Shinkawa I; Konishi A Asian J Psychiatr; 2015 Apr; 14():67-8. PubMed ID: 25736075 [No Abstract] [Full Text] [Related]
10. Induction of mania by risperidone resistant to mood stabilizers. Barkin JS; Pais VM; Gaffney MF J Clin Psychopharmacol; 1997 Feb; 17(1):57-8. PubMed ID: 9004061 [No Abstract] [Full Text] [Related]
11. Choice of and decreasing of the dosage of risperidone in the treatment of schizophrenia. Global versus individual criteria. Gómez-Perretta C Actas Esp Psiquiatr; 2007; 35(1):77-8. PubMed ID: 17323229 [No Abstract] [Full Text] [Related]
12. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study. Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481 [No Abstract] [Full Text] [Related]
13. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474 [TBL] [Abstract][Full Text] [Related]
14. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. Fuller M; Shermock K; Russo P; Secic M; Dirani R; Vallow S; Flanders S J Med Econ; 2009; 12(4):317-24. PubMed ID: 19817665 [TBL] [Abstract][Full Text] [Related]
15. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Chue P; Welch R; Binder C Can J Psychiatry; 2004 Oct; 49(10):701-3. PubMed ID: 15560318 [TBL] [Abstract][Full Text] [Related]
17. A report of successful treatment of psychosis in epilepsy with risperidone. Mahgoub NA J Neuropsychiatry Clin Neurosci; 2007; 19(3):347-8. PubMed ID: 17827431 [No Abstract] [Full Text] [Related]
18. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164 [TBL] [Abstract][Full Text] [Related]
19. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190 [TBL] [Abstract][Full Text] [Related]
20. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study. Yoshimura Y; Takeda T; Kishi Y; Harada T; Nomura A; Washida K; Yoshimura B; Sato K; Yada Y; Aoki S J Clin Psychopharmacol; 2017 Jun; 37(3):296-301. PubMed ID: 28306616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]